Aerosols for administration of systemic drugs;VOIE INHALEE POUR L'ADMINISTRATION DE MEDICAMENTS A VISEE SYSTEMIQUE

Revue des Maladies Respiratoires

Volumn 14, Issue 4, 1997, Pages 257-267

  Mallet, J P ^a   Diot, P ^a   Lemarie E ^a  

^a CHU BRETONNEAU   (France)

Author keywords

Aerosols; Respiratory epithelium; Systemic treatments

Indexed keywords

AMILORIDE; CALCITONIN; CYCLOSPORIN; FUROSEMIDE; GONADORELIN; GROWTH HORMONE; HEPARIN; INSULIN; INTERFERON; MORPHINE; NICOTINE; PROSTACYCLIN; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; CYCLOSPORIN DERIVATIVE; DIURETIC AGENT; DRUG; IMMUNOSUPPRESSIVE AGENT; NARCOTIC ANALGESIC AGENT; NICOTINIC AGENT;

AEROSOL; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; REVIEW; ANIMAL; CLINICAL TRIAL; DOG; FEMALE; MALE; RAT;

ADMINISTRATION, INHALATION; AEROSOLS; AMILORIDE; ANALGESICS, OPIOID; ANIMALS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ANTIVIRAL AGENTS; CALCITONIN; CLINICAL TRIALS; CYCLOSPORINS; DIURETICS; DOGS; EPOPROSTENOL; FEMALE; FUROSEMIDE; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE; HEPARIN; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INTERFERONS; MALE; MORPHINE; NICOTINE; NICOTINIC AGONISTS; PHARMACEUTICAL PREPARATIONS; RATS;

EID: 0030799025     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. PATTON JS, PLATZ RM : Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Del Rev 1992;8: 179-96.
2. KÖHLER D : Aerosols for systemic treatment. Lung 1990;suppl:677-84.
3. PASCAL S, DIOT P, LEMARIÉ E : Antibiothérapie en aérosols. Rev Mal Respir 1992;9:145-53.
4. MORROW PE : Aerosol characterization and deposition. Am Rev Respir Dis 1974;110:88-9.
5. KÖHLER D : Systemic therapy with aerosols. Aerosols in medecine. In : Principles, diagnosis and therapy. Moren F, Dolovich MB, Newhouse MT, Newman SP, eds. Elsevier Science Publishers BV, 1993:303-16.
6. OBERDÖRSTER G, UTELL MJ, MORROW PE, HYDE RW, WEBER DA : Bronchial and alveolar absorption of inhaled 99mTc-DTPA. Am Rev Respir Dis 1986;134:944-50.
7. CLAUZEL AM, MICHEL FB : Administration médicamenteuse par voie aérienne : reconsidération de la question. Méd Hyg 1990;48:3617-21.
8. DUGGAN CJ, DIXON CMS, IND PW : The effect of furosemide and bumetanide in exercise induced asthma. Am Rev Respir Dis 1990;141:A474.
9. O'CONNOR BJ, CHUNG KF, CHEN-WORSDELL YM, FULLER RW, BARNES PJ : Effect of inhaled furosemide and bumetanide on adenosine 5′-monophosphate-and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis 1991;143:1329-33.
10. BIANCO S, PIERONI MG, REFINI RM, ROTTOLI L, SESTINI P : Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989;321:1069-73.
11. MOSCATO G, DELLABIANCA A, FALAGIANI P, MISTRELLO G, ROSSI G,RAMPULA C : Inhaled furosemide prevents both the bronchoconstriction and the increase in neutrophil chemotactic activity induced by ultrasonic « fog » of distilled water in asthmaticc. Am Rev Respir Dis 1991;143:561-6.
12. BIANCO S, PIERONI MG, REFINI RM, ROBUSCHI M, VAGHI A, SESTINI P : Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J 1993;6:130-4.
13. SHIMUZU T, MOCHIZUKI H, MORIKAWA A, KUROUME T : Inhaled furosemide prevents ultrasonography nebulized water bronchoconstriction in children with both alopic and nonatopic asthma. Chest 1993;104:1723-26.
14. POPIN E, PAULI G: Diurétiques de l'anse et traitement de l'asthme; Rev Mal Respir 1992;9:491-4.
15. NICHOL GM, ALTON EWFW, NIX A, GEDDES DM, CHUNC KF, BARNES PJ : Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis 1990;142:576-80.
16. VERLEDEN GM, PYPE JL, DEMEDTS MG: Furosemide and bumetanide, but not nedocromil sodium, modulate nonadrenergic relaxation in guinea pig trachea in vitro. Am J Respir Crit Care Med 1994;149:138-44.
17. ELWOOD W, LÖTVALL JO, BARNES PJ, CHUNG KF : Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways. Am Rev Respir Dis 1991;143:1340-44.
18. O'DONNELL WJ, ROSENBERG M, NIVEN RW, DRAZEN JM, ISRAEL E : Acetazolamide and furosemide attenuate asthma induced by hyperventilation of cold, dry air. Am Rev Respir Dis 1992;146:1518-23.
19. BARNES PJ: Diuretics and asthma. Thorax 1993;48:195-6.
20. YATES DH, O'CONNOR BJ, YILMAZ G, AIKMAN S, WORSDELL M, BARNES PJ, CHUNG KF : Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am J Respir Crit Care Med 1995;152:2173-5.
21. LOCKHART A, SLUTSKY AS : Furosemide and loop diuretics in human asthma. Chest 1994;106:244-9.
22. KARPEL JP, DWORKIN F, HAGER D, FELICIANO S, SHAPIRO D, POSNER L, LUKS D : Inhaled furosemide is not effective in acute asthma. Chest 1994;106:1396-400.
23. TOMKIEWICZ RP, APP EM, ZAYAS JG, RAMIREZ O, CHURCH N, BOUCHER RC, KNOWLES MR, KING M : Amiloride inhalation therapy in cystic fibrosis, influence on ion content, hydration. and rheology of sputum. Am Rev Respir Dis 1993;148:1002-7.
24. APP EM, KING M, HELFESDRIEDER R, KÖHLER D, MATTHYS H : Acute and long-term amiloride inhalation in cystic fibrosis lung disease, a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990;141:605-12.
25. KNOWLES M, GATZY J, BOUCHER R : Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489-95.
26. MENTZ WM, BROWN JB, FRIEDMAN M, STUTTS MJ, GATZY JT, BOUCHER RC : Deposition, clearance, and effects of aerosolized amiloride in sheep airways. Am Rev Respir Dis 1986;134:938-43.
27. KNOWLES MR, CHURCH NL, WALTNER WE, YANKASKAS JR, GILLIGAN P, KING M et al. : A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-94.
28. GRAHAM A, HASANI A, ALTON EWFW, MARTIN GP, MARRIOTT C, HODSON ME et al. : No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243-8.
29. BOUNDY MG, LEITH D, KNOWLES MR : Dispersion and size distribution of amiloride by metered dose and dry powder inhalers. J Aerosol Med 1990;3:233-41.
30. EVERARD ML, DEVADASON SG, SUNDERLAND VB, LE SOUEF PN : An alternative aerosol delivery system for amiloride. Thorax 1995;50:517-9.
31. SOUHRADA M, SOUHRADA MH, SOUHRADA JF : The inhibition of sodium influx attenuates airway response to a specific antigen challenge. Br J Pharmacol 1988;93:884-92.
32. NETZEL M, HOPP RJ, BUZZAS R,DOWLING P, PALMEIRO E, BEWTRA AK : Effect of inhaled amiloride on the bronchial response to methacholine and cold air hyperventilation challenges. Chest 1993;103:484-7.
33. MOCHIZUKI H, SHIMIZU T, SHIGETA M, TOKUYAMA K, MORIKAWA A, KUROUME T : Effect of inhaled amiloride on water-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994;150:555-7.
34. BELLOFIORE S, DI MARIA GU, PRIVITERA S, SAPIENZA S, MILIC-EMILI J et al. : Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis 1990;142:812-6.
35. KIRSCH JL, MURO JR, STANSBURY DW, FISCHER CE, MONFORE R, LIGHT RW : Effect of naloxone on maximal exercise performance and control of ventilation in COPD. Chest 1989;96:761-6.
36. LIGHT RW, MURO JR, SATO RI, STANSBURY DW, FISCHER CE, BROWN SE : Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:126-33.
37. EISER N, LUCE P, DENMAN W, WEST C : Effect of oral diamorphine on dyspnea in chronic obstructive pulmonary disease. Am Rev Respir Dis 1990;141:A323.
38. GIRON AE, STANSBURY DW, FISCHER CE, LIGHT RW : Lack of effect of dextromethorphan on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Eur Respir J 1991;4:532-5.
39. EISER N, DENMAN WT, WEST C, LUCE P : Oral diamorphine : lack of effect on dyspnoea and exercise tolerance in the « pink puffer » syndrome. Eur Respir J 1991;4:926-31.
40. YOUNG IH, DAVISKAS E, KEENA VA : Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989;44:387-90.
41. TOOMS A, MICKENZIE A, GREY H : Nebulised morphine. Lancet 1993;342:1123-4.
42. BEAUFORD W, SAYLOR TT, STANSBURY DW, AVALOS K, LIGHT RW : Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 1993;104:175-8.
43. MASOOD AR, REED JW, THOMAS SHL : Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995; 50:629-34.
44. HARRIS-EZE AO, SRIDHAR G, CLEMENS RE, ZINTEL TA, GALLAGHER CG, MARCINIUK DD : Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 1995;152:1940-5.
45. MARTIN RJ, BOGUNIEWICZ M, HENSON JE, CELNIKER AC, WILLIAMS M, GIORNO RC et al. : The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148:1677-82.
46. JAFFE HA, BUHL R, MASTRANGELI A, HOLROYD KJ, SALTINI C, CZERSKI D et al. : Organ specific cytokine therapy, local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-γ to the human lung. J Clin Invest 1991;88:297-302.
47. KINNULA V, MATTSON K, CANTELL K : Pharmacokinetics and toxicity of inhaled human interferon-α in patients with lung cancer. J Interferon Res 1989;9:419-23.
48. HALME M, MAASILTA P, REPO H, RISTOLA M, TASKINEN E, MATTSON K et al. : Inhaled recombinant interferon gamma in patients with lung cancer : pharmacokinetics and effects on chemiluminescence response of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiation Oncology Biol Phys 1995;31:93-101.
49. DEBS RJ, FUCHS HJ, PHILIP R, MONTGOMERY AB, BRUNETTE EN, LIGGITT D et al. : Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats. J Immunol 1988;140:3482-8.
50. KESSLER R, DUMONT S, BARTHOLEYNS J, WEITZENBLUM E, POINDRON P : Antitumoral potential of aerosolized interferon-γ in mice bearing lung metastases. Am J Respir Cell Mol Biol 1994;10:202-6.
51. MCDONNALD S, RUBIN P, CHANG A, WALLENBERG J, KIM IS, SOBEL S et al. : Combined betaseron (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;suppl24:192.
52. SKERRETT SJ, MARTIN TR: Intratracheal interferon-γ augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994;149:50-8.
53. CHATTE G, PANTEIX G, PERRIN-FAYOLLE M, PACHECO Y : Aerosolized interferon gamma for mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995;152:1094-6.
54. O'RIORDAN TG, DUNCAN SR, BURCKART CJ, GRIFFITH BP, SMALDONE GC : Production of an aerosol of cyclosporine as a prelude to clinical studies. J Aerosol Med 1992;5:171-7.
55. IACONO AT, KEENAN RJ, DUNCAN SR, SMALDONE CG et al. : Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996;153:1451-5.
56. GILBERT BE, WILSON SZ, GARCON NM, WYDE PR, KNIGHT V : Characterization and administration of cyclosporine liposomes as a small-particle aerosol. Transplantation 1993;56:974-7.
57. O'RIORDAN TG, IACONO A, KEENAN RJ, DUNCAN SR, BURCKART GJ, GRIFFITH BP et al. : Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995;151:516-21.
58. ZENATI M, DUNCAN AJ, BURCKART GJ, SCHAPER M, YOUSEM SA, GRIFFITH BP et al. : Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur J Cardio-thorac Surg 1991;5:266-72.
59. KEENAN RJ, DUNCAN AJ, YOUSEM SA, ZENATI M, SCHAPER M, DOWLING RD et al. : Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 1992;53:20-5.
60. DOWLING RD, ZENATI M, BURCKART GJ, YOUSEM SA, SCHAPER M, SIMMONS RL et al. : Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 1990;108:198-205.
61. KEENAN RJ, ZEEVI A, IACONO AT, SPICHTY KJ, CAI Z-JJ, YOUSSEM SA : Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection : correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 1995;118:385-91.
62. HIGENBOTTAM T: The place of prostacyclin in the clinical management of primary hypertension. Am Rev Respir Dis 1987;136:782-5.
63. BIHARI D, SMITHIES M, GIMSON A, TINKER J : The effects of vasodilatation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 1987;317: 397-403.
64. 1 in adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 1989;139:106-10.
65. RUBIN LJ, MENDOZA J, HOOD M, MCGOON M, BARST R, WILLIAMS WB et al. : Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Internj Med 1990;112:485-91.
66. BARST RJ, RUBIN LJ, MCGOON M, CALDWELL EJ, LONG WA, LEVEY PS : Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
67. BARST RJ, RUBIN LJ, LONG WA et al. : A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
68. WALMRATH D, SCHNEIDER T, PILCH J, GRIMMINGER F, SEEGER W : Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993;342:961-2.
69. WALMRATH D, SCHNEIDER T, PILCH J, SCHERMULY R, GRIMMINGER F, SEEGER W : Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995;151:724-30.
70. OLSCHEWSKI H, WALMRATH D, SCHERMULY R, GHOFRANI A, GRIMMINGER F, SEEGER W : Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
71. SELAM JL, SLAMA G : Systèmes d'administration d'insuline, possibilités et difficultés. Presse Méd 1992;21:1575-80.
72. HANKISS J : Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J 1982;284:1707-8.
73. PONTIROLI AE, ALBERETTO M, SECCHI A, DOSSI G, BOSI I, POZZA G : Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J 1982;284:303-6.
74. MOSES AC, GORDON GS, CAREY MC, FLIER JS : Insulin administered intranasally as an insulin-bile salt aerosol : effectiveness and reproducibility in normal and diabetic subjects. Diabetes 1983;32:1040-7.
75. SALZMAN R, MANSON JE, GRIFFING GT, KIMMERLE R, RUDERMAN N, MCCALL A et al. : Intranasal aerosolized insulin, mixed-meal studies and long-term use in type I diabetes. N Engl J Med 1985;312:1078-84.
76. FRAUMAN AG, COOPER ME, PARSONS BJ, JERUMS G, Louis WJ : Long-term use of intranasal insulin-dependant diabetic patients. Diabetes Care 1987;10:573-8.
77. EL-ETR M, SLAMA G, DESPLANQUE N : Preprandial intranasal insulin as adjuvant in the type II diabetics. Lancet 1987;ii:1085-6.
78. LEE SW, SCIARRA JJ : Development of an aerosol form containing insulin. J Pharm Sci 1976;65:567-72.
79. SCHLÜTER KJ, KÖHLER D, ENZMAN F, KERP L : Pulmonary administration of human insulin in volunteers and type I-diabetics. Diabetes 1984;suppl:75A.
80. WIGLEY FM, LONDONO JH, WOOD SH, SHIPP JC, WALDMAN RH : Insulin accross respiratory by aerosol delivery. Diabetes 1971;20:552-6.
81. LAUBE BL, GEORGOPOULOS A, ADAMS GK : Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993;269:2106-9.
82. DAUGHERTY AL, LIGGITT HD, MCCABE JG, MOORE JA, PATTON JS : Absorption of recombinant methionyl-human growth hormone (Met-hGH) from rat nasal mucosa. Int J Pharm 1988;45:197-206.
83. PATTON JS, FUCHS HJ, MOORE JA, GUSTAFSON H, KELLER GA, DAUGHERTY AL : Pulmonary delivery of peptide and protein drugs. Proceed Intern Symp Control Rel Bioact Mater 1990;17:214-5.
84. COLTHORPE P, FARR SJ, SMITH IJ, WYATT D, TAYLOR G : The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm Res 1995;12:356-9.
85. ADJEI A, SUNDBERG D, MILLER J, CHUN A : Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 1992;9:244-9.
86. ADJEI A, GARREN J : Pulmonary delivery of peptide drugs : effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharma Res 1990;7:565-9.
87. KOBAYASHI S, KONDO S, JUNI K : Study on pulmonary delivery of salmon calcitonin in rats : effects of protease inhibitors and absorption enhancers. Pharm Res 1994;11: 1239-43.
88. LUENGO M, PONS F, DE OSABA MJM, PICADO C : Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapyp for asthma : a two year follow up study. Thorax 1994;49:1099-102.
89. SAMBROOK P, BIRMINGHAM J, KELLY P, KEMPLER S, NGUYEN T, POCOCK N et al. : Prevention of corticosteroid osteoporosis. a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
90. LUENGO M, PICADO C, DEL RIO L, GUANABENS N, MONTSERRAT JM, SETOAIN J : Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990;142:104-7.
91. OVERGAARD K, HANSEN MA, JENSEN SB, CHRISTIANSEN C : Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis : a dose-response study. Br Med J 1992;305:556-61.
92. NEGRO RD, TURCO P, POMARY C, TREVISAN F: Calcitonin nasal spray in patients with chronic asthma : a double-blind crossover study vs placebo. Int J Clin Pharmacol Ther Toxicol 1991;29:144-6.
93. BURCH SG, ERBLAND ML, GANN LP, HILLER FC : Plasma nicotin levels after inhalation of aerosolized nicotine. Am Rev Respir Dis 1989;140:955-7.
94. PRIGNOT J : Pharmacological approach to smoking cessation. Eur Respirf J 1989;2:550-60.
95. BURCH SG, ERBLAND ML, GANN LP, HILLER FC : Plasma nicotine levels after inhalation of aerosolized nicotine. Am Rev Respir Dis 1988;137:A159.
96. HERRMANN DR, OLSEN KM, HILLER FC : Nicotine absorption following pulmonary instillation. Am Rev Respir Dis 1989;139:A334.
97. BURCH SG, GANN LP, OLSEN KM, ERBLAND ML, HILLER FC : Effect of aerosol particle size on nicotine absorption and side effects produced by nicotine aerosol. Am Rev Respir Dis 1989;139:A339.
98. BURCH SG, GANN LP, OLSEN KM, ANDERSON PJ, HILLER FC, ERBLAND ML : Effect of pH on nicotine absorption and side effects produced by aerosolized nicotine. J Aerosol Med 1993;6:45-51.
99. WRIGHT CJ, MAHADOO J, JACQUES LB : Anticoagulant activity and operative blood loss after intrapulmonary heparin. Br J Surg 1979;66:844-7.
100. JACQUES LB, MAHADOO J, KAVANAGH LW : Intrapulmonary heparin, a new procedure for anticoagulant therapy. Lancet 1976;27:1157-61.
101. BICK RL, Ross ES : Clinical use of intrapulmonary heparin. Semin Thromb Hemost 1985;11:213-7.
102. MAHADOO J, HIEBERT LM, JACQUES LB, WRIGHT CJ : Endothelial sequestration of heparin administered by the intrapulmonary route. Artery 1980;7(5):438-47.
103. MAHADOO J, HIEBERT LM, WRIGHT CJ, JACQUES LB : Vascular distribution of intratracheally administered heparin. Ann Ny Acad Sci 1981;370:650-5.
104. KÖHLER D : Aerosolized heparin. J Aerosol Med 1994;7:307-14.
105. SHULMAN AG : Heparin for prevention of atherosclerosis. N Eng J Med 1988;319:1154-5.
106. LANE DA, ADAMS L : Non-anticoagulant uses of heparin. N Engl J Med 1993;329:129-30.
107. AHMED T, ABRAHAM WM, D'BROT J : Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 1992;145:566-10.
108. INASE N, SCHRECK RE, LAZARUS SC : Heparin inhibits mast cell histamine release. Am Rev Respir Dis 1992;145:A852.
109. VIRCHOW JR JC, VENGE P, VIRCHOW SEN C: Eosinophil cationic protein in sputum from asthmatic patients with sputum eosinophilia. Am Rev Respir Dis 1991;143:A41.
110. COX CS, ZWISCHENBERGER JB, TRABER DL, TRABER LD, HERNDON DN : Beneficial effects of heparin after smoke inhalation injury not due to decreased oxygen free radical activity. Am Rev Respir Dis 1992;145:A80.
111. AHMED T, GARRIGO J, DANTA I : Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993;329:90-5.
112. CEYHAN B, CELIKEL T : Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 1995; 107:1009-12.